🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Sinocelltech clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Sinocelltech as lead sponsor. Synced 26 Sep 2026
20Current trials
13Recruiting now
17Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Sinocelltech is the lead sponsor of 20 current clinical trials in our China register. 13 are recruiting patients now. The most common phase is Phase 1/2. The drugs named most often in its trials are SCTB41, SCTB35 and Lenalidomide. The most-studied condition is Advanced Malignant Solid Tumor.

ClinicalTrials.gov trials by status

  • Recruiting1365%
  • Not yet open630%
  • Active, closed15%

Trials by phase

  • Phase 1/2945%
  • Phase 3735%
  • Phase 1210%
  • Phase 215%
  • Phase 2/315%
01

Clinical trials sponsored by Sinocelltech

20 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
NCT07562022 · Follicular Lymphoma (FL)
Phase 3 Recruiting 2026-06 China
Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.
NCT07437404 · ClinicalTrials.gov ↗ · Haemophilia A
Phase 3 Recruiting 2024-04 China
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT07570823 · ClinicalTrials.gov ↗ · DLBCL - Diffuse Large B Cell Lymphoma
Phase 3 Recruiting 2026-06 China
A Study of SCTB35 in Patients with Systemic Lupus Erythematosus
NCT06841042 · ClinicalTrials.gov ↗ · System Lupus Erythematosus
Phase 1/2 Recruiting 2025-02 China
SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
NCT07662395 · ClinicalTrials.gov ↗ · Double Blind
Phase 2/3 Recruiting 2026-05 China
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine
NCT06754605 · ClinicalTrials.gov ↗ · Respiratory Syncytial Virus
Phase 1/2 Recruiting 2025-02 China
A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.
NCT07362459 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Carcinoma (NSCLC)
Phase 3 Recruiting 2025-12 China
A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies
NCT06252298 · ClinicalTrials.gov ↗ · Relapsed or Refractory Hematologic Malignancies
Phase 1 Recruiting 2024-02 China
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)
NCT07388602 · ClinicalTrials.gov ↗ · Amyloidosis
Phase 3 Recruiting 2026-01 China
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
NCT07297329 · ClinicalTrials.gov ↗ · Multiple Myeloma (MM)
Phase 3 Recruiting 2025-12 China
Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.
NCT06600022 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Tumours
Drug: SCTB41
Phase 1/2 Recruiting 2024-10 China
Phase I/II Study of SCTB39-1 in Advanced Solid Tumours
NCT07050641 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Tumor
Phase 1/2 Recruiting 2025-06 China
Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD
NCT06672536 · ClinicalTrials.gov ↗ · nAMD
Phase 1/2 Recruiting 2024-11 China
SCTB35 and SCTB41 With or Without Chemotherapy in Non-Hodgkin Lymphoma
NCT07819188 · ClinicalTrials.gov ↗ · NHL - Non-Hodgkin's Lymphoma
Drugs: SCTB35, SCTB41
Phase 1/2 Not yet open 2026-09 China
A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(Phase II Study Ongoing)
NCT07609251 · ClinicalTrials.gov ↗ · NSCLC (Advanced Non-small Cell Lung Cancer)
Phase 2 Not yet open 2026-05 China
A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma
NCT06318884 · ClinicalTrials.gov ↗ · Non-Hodgkin Lymphoma, B-cell
Phase 1 Not yet open 2024-04 China
A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases
NCT06774664 · ClinicalTrials.gov ↗ · IgA Nephropathy
Drug: SCTC21C
Phase 1/2 Not yet open 2025-01 China
Phase I/II Study of SCTB39G in Advanced Solid Tumours
NCT07077252 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Tumor
Phase 1/2 Not yet open 2025-07 China
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine
NCT06801509 · ClinicalTrials.gov ↗ · Herpes Zoster
Phase 1/2 Not yet open 2025-02 China
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years
NCT06041061 · ClinicalTrials.gov ↗ · HPV InfectioN, HPV-Related Carcinoma
Phase 3 Active, closed 2023-08 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Sinocelltech trials

17 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Sinocelltech trials

20 conditions
Advanced Malignant Solid Tumor2Follicular Lymphoma (FL)1Haemophilia A1DLBCL - Diffuse Large B Cell Lymphoma1NHL - Non-Hodgkin's Lymphoma1System Lupus Erythematosus1NSCLC (Advanced Non-small Cell Lung Cancer)1Double Blind1Respiratory Syncytial Virus1Non-Hodgkin Lymphoma, B-cell1Non-Small Cell Lung Carcinoma (NSCLC)1Relapsed or Refractory Hematologic Malignancies1IgA Nephropathy1Amyloidosis1Multiple Myeloma (MM)1Advanced Malignant Solid Tumours1Herpes Zoster1HPV InfectioN1HPV-Related Carcinoma1nAMD1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China2013

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Advanced Malignant Solid Tumor

SponsorTrials
Minghui Pharmaceutical (Hangzhou)6
Jiangsu Alphamab Biopharmaceuticals2
Suzhou Maximum Bio-tech1

Sponsors with the most current trials registered for this condition.

06

Questions about Sinocelltech trials

How many clinical trials does Sinocelltech sponsor?

Sinocelltech is the lead sponsor of 20 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Sinocelltech trials recruiting?

Yes. 13 of its 20 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Sinocelltech testing?

Its current trials name 17 drugs and biologicals as interventions. The most frequent are SCTB41 (4), SCTB35 (3), Lenalidomide (2), SCTC21C (2) and Bortezomib (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.